Skip to content

Upstream Bio, Inc. UPB Operating Cash Flow

Operating Cash Flow at other companies

Amgen logo
AmgenAMGN
$2.19B+57.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.08B+3.2%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$18.15M-39.0%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$13.42M-11.6%
Savara logo
SavaraSVRA
-$33.05M-21.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$25.92M-142%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s operating cash flow?
Upstream Bio, Inc. (UPB) reported operating cash flow of -$47.85M in Q1 2026.
How has Upstream Bio, Inc.'s operating cash flow changed year-over-year?
Upstream Bio, Inc.'s operating cash flow decreased by 16.2% year-over-year, from -$41.17M to -$47.85M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.